All In Biotech

Drug Trial Radar · NCT02349802

Autoinjector Device Assessment Study

Evaluation of the Single-Use Pre-Filled Autoinjector

Last checked: Nov 20, 2026Latest source record: Feb 2, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 3,052 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,052

Actual

Start

Feb 2013

Primary completion

Dec 2013

Study completion Dec 2013

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Celerion
First posted
Jan 29, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase I study to determine the device-related injection failure rate of the single-use, pre-filled autoinjector.

Conditions

  • Healthy Subjects

Interventions

  • Auto-injector with exenatide suspensionDrug

    A flexible study design to accommodate multiple cohorts.

  • Syringe with exenatide suspensionDrug

    A flexible study design to accommodate multiple cohorts.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of device-related failure injectionsTime frame: 10 week study

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Tempe, Arizona

  • Research Site

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.